At the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021), held in April 2021, Dr. Kim Papp from the Probity Medical Research, Waterloo, Ontario, Canada, presented this paper.
Scalp, nail, and palmoplantar psoriasis are associated with impaired quality of life (QoL), patients may experience substantial physical/functional impairment (including psoriatic arthritis, which is more common with nail involvement), psychologic stress, social discomfort, and reduced work productivity.
Topical agents may not be effective or well tolerated in these difficult-to-treat areas of the body . Ixekizumab is a drug with a high-affinity monoclonal antibody that selectively targets interleukin-17A and demonstrated efficacy in patients with psoriasis in burdensome areas for up to 5 years.
UNCOVER-2 study (NCT01597245) is a randomized, double-blind, multicenter, Phase 3 clinical trial of ixekizumab for the treatment of moderate-to-severe plaque psoriasis. Ixekizumab maintains long-term efficacy and a safety profile consistent with previous data in patients with moderate-to-severe plaque psoriasis through 5 years of treatment.
The objectives of the study was to evaluate the long-term efficacy, safety, and QoL of the approved dose of ixekizumab through 5 years in patients with psoriasis involving the difficult-to-treat areas of scalp, nails, palms, and soles.
Patients with ≥18 years old with moderate-to-severe plaque psoriasis were enrolled in the study . The patients had to present : Area and Severity Index ≥12 at the screening and baseline visits , ≥10% body surface area affected at the screening and baseline visits and Static Physician’s Global Assessment (sPGA) score ≥3 at the screening and baseline visits. Was excluded those who had received prior etanercept use or other forms of psoriasis or history of drug-induced psoriasis.
Consistent with previous findings, ixekizumab sustained high efficacy in patients with psoriasis in burden some areas with high levels of skin clearance and minimal tono impact on QoL through 5 years of treatment. The overall safety profile was consistent with that reported in the psoriasis clinical trial program.
- FECHA: 28/04/2023